Arcus Biosciences Inc (RCUS) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Total Assets Chart for Arcus Biosciences Inc
Arcus Biosciences Inc (RCUS) total assets for FY2025 were USD 1.1B, a -1.0% change from FY2024. Arcus Biosciences Inc's total assets grew from USD 109.7M in 2016 to USD 1.1B in 2025 (938.3% over 9 years). Total assets compound annual growth rate: 5-year CAGR of 8.1%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $2.33B
- Implied Share Price
- $18.54
- Enterprise Value
- $2.55B
- Revenue (TTM)
- $117.00M
- EBITDA
- -$476.00M
- Profit Margin
- 0.00%
- Trailing P/E
- —
- Forward P/E
- 0.00
- Price/Book (MRQ)
- 6.76
- Price/Sales (TTM)
- 19.93
- EV/EBITDA
- 3.96
- EV/Revenue
- 21.80
- Dividend Yield
- —
- Book Value
- $3.65
- Free Cash Flow (FY2025)
- -$484.00M
- Free Cash Flow Yield
- -20.76%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.